963 results about "Liver damage" patented technology

This invention concerns the method of extracting salvianolic acid A from Chinese crude drug: danshen root, and the quality control methods and drug combinations, and the application of this drug. It can be used in the preparation of the prevention drugs for cardiovascular disease, liver damage, liver fibrosis, pulmonary fibrosis and other.

The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.

Disclosed are uses of immunotherapeutic compositions in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the improved treatment of chronic hepatitis C virus (HCV) infection and related conditions, including liver function. The compositions, kits and uses of the invention, as compared to the use of SOC therapy alone: improves the rate of early response to therapy as measured by early virologic markers (e.g., RVR and EVR), enlarges the pool of patients who will have sustained responses to therapy over the long term, offers shortened courses of therapy for certain patients, enables “rescue” of patients who are non-responders or intolerant to SOC therapy, improves liver function and / or reduces liver damage in patients, and enables the personalization of HCV therapy for a patient, which can result in dose sparing, improved patient compliance, reduced side effects, and improved long term therapeutic outcomes.

The present invention relates to 5-thia-omega-substituted phenylprostaglandin E derivatives of the formula (I)(wherein, all the symbols are as defined in the specification), process for producing them and pharmaceutical compositions comprising them as active ingredient.The compounds of the formula (I) can bind to PGE2 receptors (especially, subtype EP4) strongly, so they are expected to be useful for prevention and / or treatment of immunological diseases (autoimmune diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, Sjoegren's syndrome, chronic rheumarthrosis and systemic lupus erythematosus etc., and rejection after organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, lung failure, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardiac ischemia, systemic inflammatory response syndrome, ambustion pain, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, and shock etc. Further, it is thought that EP4 subtype receptor relates to sleeping disorder and blood platelet aggregation, so the compounds of the present invention are expected to be useful for the prevention and / or treatment of such diseases.

The invention relates to a silibinin monoester derivative and its medicine salt or solvates. The invention also relates to its preparation method and its drug combination and medical application. The compound can inhibit activity of hepatitis b virus, so it is expected to be used as drug to treat hepatitis b virus and relevant virus diseases. The compound can protect liver and is expected to be used as drug preventing liver damage. The compound possesses effect anti free radical and is expected to be used as drug treating diseases caused by free radical.

The invention provides a product having sobering up and liver protecting functions and its preparation method and use, which comprises the following raw material (by weight ratio), soybean peptides and soybean extract 2.5-12:0.5, panaxoside or ginkgo leaf extract, green tea polyphenols, glutacid, arginine or lycine, vitamin C, vitamin B6, vitamin B1, vitamin B2 or vitamin B12. The medicament can be made into various dose forms including capsule, oral liquid, tablet, effervescent tablet or injection.

The invention discloses a chitosan oligosaccharide capsule; chitosan oligosaccharide with 2000-10000 of molecular weight, radix salviae miltiorrhizae extract, pueraria root extract, obtuseleaf senna seed extract and schisandra extract are used as main materials; starch and magnesium stearate are taken as auxiliary raw materials; the weight components of the formula of the chitosan oligosaccharide capsule include the chitosan oligosaccharide, the radix salviae miltiorrhizae extract, the pueraria root extract, obtuseleaf senna seed extract, schisandra extract, the starch and the magnesium stearate; the production process of the capsule is that: sieving, weighting, mixing, capsule filling, polishing, screening, inside and outside package, warehouse-in inspection are carried out to prepare the health-care product. The chitosan oligosaccharide capsule has the advantages that the main composition of the capsule comprises the chitosan oligosaccharide, general flavone and total anthraquinone; the capsule is taken orally two times one day, 3 granules each time, and the capsule has auxiliary protection function to the chemical liver damage.

The present invention relates to an SNP (single nucleotide polymorphism) combination, detection method and kit for detecting liver damage susceptible genotype of an antitubercular drug and belongs to the technical field of medical molecular biological diagnosis; the SNP combination includes 7 SNP sites, and nucleotide sequences of the 7 SNP sites are shown sequentially as in SEQ ID NO. 1-7; the present invention also relates to an SNP detection method, comprising PCR (polymerase chain reaction) amplification and double-labeled probe melting curve analytical reaction, and primer pairs and double-labeled probe sequences for detection of the 7 SNP sites are shown as in SEQ ID NO. 8-20. The SNP site combination, detection method and kit provided herein enables quick, accurate, simple and high-throughput detection for a patient's genotype and prediction for the liver damage risk due to the patient using the antitubercular drug.

The present invention relates to the discovery of an epigenetic relay pathway that controls hepatic stellate cell activation and the wound-healing response in fibrogenesis, including fibrogenesis of the injured liver. Methods of inhibiting fibrogenesis, including liver fibrogenesis and secondary disease states and conditions thereof, and in treating liver damage, including cirrhosis of the liver (which may be caused by viruses or chemicals, including alcohol), are aspects of the present invention. The methods utilize certain nucleoside compounds and / or antibodies which are optionally conjugated. Pharmaceutical compositions represent additional aspects of the invention.

The present invention relates to a non-transgenic, non-human animal useful as a model for protease activity and for liver damage, including steatosis.

The invention relates to anthropogenic lactobacilus fermentum grx07 with a protection role on chronic alcoholic liver damage and application thereof. The lactobacilus fermentum grx07 strain disclosed by the invention is a probiotic strain separated from intestinal tracts of people in a Rugao longevity village of Jiangsu, the strain is preserved in China General Microbiological Culture Collection Center, and the preservation number is CGMCC No.8874. The lactobacilus fermentum grx07 strain has significant in vitro antioxidant ability and pathogenic bacteria inhibition ability, the rat blood fat of chronic alcoholic liver damage and the toxin level in serum can be significantly reduced, expression of liver inflammatory cytokines is reduced, the inflammatory reaction of the liver is relieved, the expression quality of antioxidant specific protein Nrf2 of the liver is increased, and the liver cell apoptosis percentage is reduced. Therefore, the anthropogenic lactobacilus fermentum grx07 has a significant protective effect on the chronic alcoholic liver damage.

The present invention presents compounds that inhibit phosphodiesterase 4 having Formula (I). The present invention also provides methods of using the compounds of Formula (I) to prevent or treat asthma, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disorders, pulmonary hypertension, liver injury, bone loss, septic shock, or multiple sclerosis, and to pharmaceutical compositions that contain the compounds of Formula (I).

The present invention provides methods for the treatment and / or prevention of thrombocytopenia including thrombocytopenia associated with drug-induced liver damage and thrombocytopenia associated with drug-induced bone marrow destruction. The methods of treatment of the invention include administration of interleukin-11 to a subject suffering from or susceptible to thrombocytopenia and / or receiving or about to receive a treatment involving a conjugate therapeutic agent whose administration results in thrombocytopenia. Also provided are pharmaceutical compositions and kits useful for carrying out such methods of treatment.

The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.

The invention discloses application of fructus forsythiae aglycone in preparing a medicament for preventing or treating liver injury or liver failure, and belongs to the medical field. The fructus forsythiae aglycone is a traditional Chinese medicine monomer obtained by extracting from the conventional fructus forsythiae, and is shown to have better treatment effect for the liver injury caused by acetaminopben, the livery injury caused by anti-tumor drug cis-platinum, acute or chronic livery injury caused by carbon tetrachloride, the livery injury caused by D-galactosamine and the liver failure caused by the D-galactosamine and lipopolysaccharide according to an animal test, has effect, which is better than that of fructus forsythiae and fructus forsythiae aglycone, in treating liver injury or liver failure. The fructus forsythiae aglycone is exact in curative effect and low in side effect for treating the liver injury and the liver failure, and has wide medical application prospect.

The present invention provides low cost and highly effective method for the removal of arsenic and Cr(III&VI) from contaminated water using zinc peroxide nanoparticles (20±5 nm) capped with glycerol / PVP / TEA upto the permissible range of drinking water. As Arsenic and chromium occurs naturally in the earth's crust. When rocks, minerals, and soil erode, they release arsenic and chromium into groundwater. Arsenic and chromium occurs naturally in varying amounts in groundwater in various parts of country from ppb level to ppm level. The average concentration of arsenic and chromium as per USEPA standard in drinking water it is 10 parts per billion and 0.05 ppm (50 ppb) respectively. In drinking water the level of chromium is usually low as well, but contaminated water may contain the dangerous Cr(III&VI). Although Cr(III) is an essential nutrient for humans and shortages may cause heart problems, disruptions of metabolisms and diabetes. But the uptake of too much Cr(III) can cause health effects as well, for instance skin rashes. Cr(VI) is known to cause various health effects Skin rashes, upset stomachs, respiratory problems, weakened immune systems, kidney and liver damage and lung cancer The persons who are drinking water having upto 50 ppb of arsenic and 0.05 ppm chromium over for many years could experience skin damage or problems with their circulatory system, and may have an increased risk of getting cancer. Keeping the above facts we developed a cost effective nanoparticles for the removal of Arsenic and Cr(III&VI) from potable water upto potable range.

The invention discloses a corn sobering-up peptide and a preparation method thereof. In the method, corn gluten meal is taken as a raw material for the product provided by the invention, alkali protease Alcalase is adopted for hydrolysis for 2 hours under optimal conditions, compound protease Protamex is further added for hydrolysis for 3 hours under the optimal conditions, and corn sobering-up peptide powder is obtained by crude separation, ultrafiltration, concentration and spray forming. The peptide section with the molecular weight of less than 1200Da in the product accounts for 73.19%, and the content of lactamic acid and the content of aminocarproic acid are greater than 6.43% and 12.42% respectively. The product can generate stable nicotinamide adenine adinucleotide (NAD<+>) by improving the concentration of the lactamic acid and aminocarproic acid in blood, enhance the activity of alcohol dehydrogenase and acetaldehyde dehydrogenase, promote decomposition and metabolism of ethanol in vivo, thereby reducing the concentration of the ethanol in the blood, increasing the supply of coenzyme, playing a role in protecting liver and playing a role in preventing liver damages caused by alcohol, such as fatty liver and the like.

The present invention relates to a compound of Antrodia camphorata used for liver protection, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone which is isolated from Antrodia camphorata. The cyclohexenone compound according to the invention helps to alleviate liver injury and fibrosis induced by chemicals and reduces the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). By increasing the contents of glutathione peroxidase (GSHPx) and catalase (CAT), cyclohexenone further decreases the liver damage and the oxidative pressure caused by free radicals, enhances the antioxidant ability and achieves the purposed of liver protection.

The invention relates to a silibinin flavonolignan and its medicine salt or solvates. The invention also relates to the method preparing its important mediate and its drug combination and medical application. The compound can protect primary hepatocyte from oxidative damage for SD newly born rat hepatitis virus, so it is expected to be used as drug preventing liver damage. The compound can remove superoxide anion free radical and diphenyl picryl phenylhydrazine free radical, inhibit free radical from inducing generation of fat oxidatant, protect PC 12 cell from being damaged by free radical, so it is expected to be used as drug treating diseases caused by free radical.

The present invention relates to health preserving and liver protecting tea and its preparation process. The health preserving and liver protecting tea is prepared with nine kinds of Chinese medicinal materials, including gynostemma pentaphylla, haw, wolfberry fruit, red sage, fleeceflower root, etc in certain weight proportion, and through water decoction or alcohol extraction, mixing, drying, frying, bagging, Co-60 irradiation and other steps. The medicinal tea contains rich nutrients, and animal experiment and practical application proves its functions of preventing and treating chemical liver damage, raising body's immunity and helping treatment of fatty liver and no toxic side effect.

The invention discloses an artemisia sacrorum extract which contains total-flavone compounds, wherein the total-flavone compounds comprise one or more of 6-methoxy-quercetagetin-7-O-beta-D-glucoside, quercetin-3-O-beta-D-glucoside, isorhamnetin, queretagetin-3-O-beta-D-glucoside, acacetin-7-O-beta-D-glucoside, rutin, 5,7,4'-trihydroxyflavone, 3,3',4',5,7-pentahydroxyflavone, 5,7,4'-trihydroxy-3'-methoxyflavone, kaempferol, 3,5,7,4'-tetrahydroxy-6-methoxyflavone, 3',4',5,7-tetrahydroxyflavone, 5,7,4'-trihydroxy-6,3'-dimethoxyflavone, 5,7,4'-trihydroxy-6-methoxyflavone, quercitrin, 7,3',4'-trimethyl quercetin, 5-hydroxy-7,4'-dimethoxyflavone, 5,4'-dihydroxy-7-methoxyflavone genkwanin, 5,7-dihydroxy-4'-methoxyflavone, 5,7,3'-dihydroxy-4-methoxyflavone and derivatives. The artemisia sacrorum extract has remarkable prevention and treatment effects on liver injury.

The invention discloses an industrial production method of high-F-value corn oligopeptide with alcohol dispelling and liver protection activities. The production method comprises the following steps: carrying out high-speed shearing emulsification on corn gluten meal (CGM), carrying out enzymolysis by combining basic protein with compound flavored proteinase, carrying out enzyme deactivation and frame filtering, carrying out activated carbon adsorption to remove bitterness, colors and aromatic amino acid, carrying out separation and purification by virtue of ultrafiltration equipment, carrying out desalination by virtue of nanofiltration, and carrying out spray drying, so as to obtain the high-F-value corn oligopeptide. According to the high-F-value corn oligopeptide produced by virtue of the production method, the fatty degeneration index of liver cells of mice with alcoholic hepatic injury can be decreased, meanwhile, the contents of triglyceride (TG) and malondialdehyde (MDA) in the livers can be reduced, and the content of reduced glutathione (GSH) can be increased; and a result shows that the high-F-value corn oligopeptide produced by virtue of the production method has the effect of preventing the alcoholic hepatic injury of the mice.

The invention belongs to the field of food health protection, and particularly discloses a preparation method and application of turmeric fruit and vegetable enzyme. The preparation method comprises the following steps: (1) cleaning, airing and smashing fruits and vegetables to obtain a mixed fruit and vegetable solution; (2) adding sugar into the mixed fruit and vegetable solution, inoculating saccharomycetes, carrying out sealed fermentation, and when the pH is less than 4.3, obtaining primary fermented liquid; (3) inoculating compound lactobacillus into the primary fermented liquid for secondary fermentation, wherein the compound lactobacillus comprises lactobacillus plantarum, lactobacillus casei and bacillus aceticus; carrying out sealed fermentation, and when the pH is less than 3.8, adding a turmeric extract into the fruit and vegetable solution for continuous fermentation for 10 days to obtain secondary fermented liquid; (4) filtering or centrifuging the secondary fermented liquid, and homogenizing and sterilizing filtrate or centrifuged supernate to obtain the turmeric fruit and vegetable enzyme. The prepared turmeric fruit and vegetable enzyme has a liver protecting effect, and is suitable for long-term prevention and health care application of people working under a high chemical liver injury risk environment.

The invention is related to methods of treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases.

The invention discloses a making method of four new substituted phenyl flavonols (1-4) compound, eight new sesquiterpenoids (5-12), one new dihydrochalcone (13) and eight known compound (14-21), which contains drug composition with effective component of sarcandra glabra as well as the application in the liver-damage protecting drug.

The present invention relates to an anti-free radical oxidation, liver-protective, senile dementia preventing and anti-aging active dehydrogenation silybin double-ester derivative and the related medicinal salt or solvent compound. The invention also relates to the preparation method for the compound on the formula 1, as well as the related medication compounds and the curatorial uses. The compound of the invention can protect the liver cells of a rat liver cell injury in vitro model, which can be expected to prevent liver damage in drug use; the compound of the invention is provided with the biological activities of in vitro removing superoxide anion free radicals and diphenyl-benzyl-hydrazine free radicals, and restraining generation of grease peroxide induced by free radicals. The compound can strongly confront the PC12 cells damage caused by free radicals, which can be expected to prevent various diseases caused by free radicals in drug use.

The invention discloses a traditional Chinese medicine composition used for curing chronic hepatitis and a preparation method thereof. The traditional Chinese medicine composition is made of raw material medicines with the weight proportion by parts: 40 to 160 parts of Chinese thorowax root, 40 to 160 parts of debark peony root, 40 to 160 parts of angelica, 40 to 160 parts of India madder root, 40 to 160 parts of largehead atractylodes rhizome, 40 to 160 parts of Tuckahoe, 40 to 160 parts of turtle carapace, 40 to 160 parts of massa medicata fermentata hunanensis, 60 to 240 parts of Codonopsis pilosula nannfeldt, 60 to 240 parts of Lalang Grass Rhizome, 24 to 96 parts of immature orange fruit, 20 to 80 parts of green tangerine peel, 12 to 48 parts of villous amomum fruit, 12 to 48 parts of earthworm and 12 to 48 parts of liguorice. The traditional Chinese medicine composition of the invention has the pharmacological efficacies of antagonizing hepatic damage, protecting liver, regulating immune function, reducing aminopherase, improving liver function and on the like, and the clinical efficacy observation experiments prove that the traditional Chinese medicine composition has the exact efficacies to the chronic hepatitis, in particular to chronic active hepatitis, chronic persisting hepatitis and early cirrhosis; and the clinical application is of safety and no toxicity and side effects.